Cambridge, Mass., USA – ImmusanT, a biopharmaceutical company, announced that Ferdinand E. Massari has joined the company as senior vice president, development
and chief medical officer.[break]
Dr. Massari has more than 20 years of experience in all stages of drug development and comes to ImmusanT having most recently served as a consultant providing product candidate evaluation and clinical plan development services to companies and investors.
Previously, Dr. Massari was Global Head and Vice President of Clinical and Medical Affairs at Shire Human Genetic Therapies, where he was responsible for the oversight of global development of products to treat rare genetic disorders.
Earlier, Dr. Massari served as Senior Vice President of Drug Development and Chief Medical Officer at Coley Pharmaceutical Group where he oversaw the development of novel therapeutics for hepatitis C infection and lupus. Dr. Massari has held executive positions at Pfizer where he led clinical programs for ZYVOX (linezolid), one of the most successful hospital antibiotics to date.
He began his career at Merck where he was its first HIV - September 10, 2013, Cambridge, Mass., USA – ImmusanT, a biopharmaceutical company, announced that Ferdinand E. Massari has joined the company as senior vice president, development
and chief medical officer.
Article continues below
]
Dr. Massari has more than 20 years of experience in all stages of drug development and comes to ImmusanT having most recently served as a consultant providing product candidate evaluation and clinical plan development services to companies and investors.
Previously, Dr. Massari was Global Head and Vice President of Clinical and Medical Affairs at Shire Human Genetic Therapies, where he was responsible for the oversight of global development of products to treat rare genetic disorders.
Earlier, Dr. Massari served as Senior Vice President of Drug Development and Chief Medical Officer at Coley Pharmaceutical Group where he oversaw the development of novel therapeutics for hepatitis C infection and lupus. Dr. Massari has held executive positions at Pfizer where he led clinical programs for ZYVOX (linezolid), one of the most successful hospital antibiotics to date.
He began his career at Merck where he was its first HIV-trained physician-scientist and served as Director, Clinical Research, Infectious Disease. Dr. Massari is board certified in internal medicine and trained in allergy and immunology in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. ■